IO comes agonisingly close to success
Keynote-D18 might have failed on a technicality, but now cash is running out.
ALX's conjugate foray goes clinical
ALX2004 starts phase 1, along with the sixth oncology-focused in vivo Car-T.
Arvinas rules out a solo vepdegestrant launch
If Pfizer hands back the estrogen receptor degrader, Arvinas will seek a new partner.
Bristol takes its bispecific conjugate into lung cancer
A second global pivotal trial will test iza-bren in the same NSCLC setting where patri-dxd failed.
Y-Mabs falls to Serb
The speciality pharma will gain the approved Danyelza and a radiopharma pipeline.
